Lyell Immunopharma (LYEL) Operating Leases (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Operating Leases data on file, last reported at $39.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 30.83% year-over-year to $39.5 million; the trailing twelve-month figure through Mar 2026 stood at $39.5 million (down 30.83% YoY), and the FY2025 full-year result was $41.9 million, down 17.79% from the prior year.
• Operating Leases eased to $39.5 million in Q1 2026, from $41.9 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $68.8 million in Q1 2022 to a low of $39.5 million in Q1 2026.
• A 5-year average of $58.2 million and a median of $58.6 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases advanced 9.84% in 2022 and tumbled 30.83% in 2026, its largest moves.
• Tracing LYEL's Operating Leases over 5 years: stood at $63.2 million in 2022, then decreased by 9.93% to $56.9 million in 2023, then decreased by 10.37% to $51.0 million in 2024, then decreased by 17.79% to $41.9 million in 2025, then retreated by 5.81% to $39.5 million in 2026.
• Business Quant data shows LYEL's Operating Leases at $39.5 million in Q1 2026, $41.9 million in Q4 2025, and $53.1 million in Q3 2025.